key: cord-0298454-iepurqgd
authors: Taeschler, P.; Cervia, C.; Zurbuchen, Y.; Hasler, S.; Pou, C.; Tan, Z.; Adamo, S.; Raeber, M. E.; Baechli, E.; Rudiger, A.; Stuessi-Helbling, M.; Huber, L. C.; Brodin, P.; Nilsson, J.; Probst-Mueller, E.; Boyman, O.
title: Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures
date: 2022-01-10
journal: nan
DOI: 10.1101/2022.01.08.22268901
sha: cee33702fe8e6f342b9cb1b221ef01d545f4efe3
doc_id: 298454
cord_uid: iepurqgd

Background: Several autoimmune features occur during coronavirus disease 2019 (COVID-19), with possible implications for disease course, immunity, and autoimmune pathology. Objective: We longitudinally screened for clinically relevant systemic autoantibodies to assess their prevalence, temporal trajectory, and association with immunity, comorbidities, and severity of COVID-19. Methods: We performed highly sensitive indirect immunofluorescence assays to detect anti-nuclear antibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCA), along with serum proteomics and virome-wide serological profiling in a multicentric cohort of 175 COVID-19 patients followed-up to one year after infection, eleven vaccinated individuals, and 41 unexposed controls. Results: Compared to healthy controls, similar prevalence and patterns of ANA were present in patients during acute COVID-19 and recovery. However, paired analysis revealed a subgroup of patients with transient presence of certain ANA patterns during acute COVID-19. Furthermore, patients with severe COVID-19 exhibited a high prevalence of ANCA during acute disease. These autoantibodies were quantitatively associated with higher SARS-CoV-2-specific antibody titers in COVID-19 patients and in vaccinated individuals, thus linking autoantibody production to increased antigen-specific humoral responses. Notably, the qualitative breadth of antibodies cross-reactive with other coronaviruses was comparable in ANA-positive and ANA-negative individuals during acute COVID-19. In autoantibody-positive patients, multiparametric characterization demonstrated an inflammatory signature during acute COVID-19 and alterations of the B cell compartment after recovery. Conclusion: Highly sensitive indirect immunofluorescence assays revealed transient autoantibody production during acute SARS-CoV-2 infection, while the presence of autoantibodies in COVID-19 patients correlated with increased anti-viral humoral immune responses and inflammatory immune signatures.

solution and stained with antibodies (Beckman Coulter; Table S3 ). Absolute cell counts were 170 determined using Flow Set Pro Fluorospheres calibration beads on Navios (Beckman Coulter). 171 172 Serum proteomics 173 Serum samples were analyzed by a proximity extension assay-based technology 92-plex 174 inflammation panel (Olink ® ), as established (26) (27) (28) . Six parameters were excluded because 175 less than 50% of samples showed results above detection limit. 176

177 Human virome-wide serological profiling 178

As established (7, 29), serum samples were inactivated, normalized for total IgG concentration, 179 and incubated as duplicates with a bacteriophage library displaying linear, 56 amino acid long 180 viral epitopes. IgG-phage complexes were captured with magnetic beads, lysed and quantified 181 by next-generation sequencing. Blank beads samples were used as negative controls. Reads 182 were mapped to the epitope library with Bowtie2, and counts were obtained using SAMtools. 183 A previously described binning strategy was used to identify positivity for epitopes ((30)), with 184 a minimum z-score of 3.5 for both sample replicates compared to negative controls. Results for 185 a total of 112 different human viruses were included in the further analysis. (Table S4) , 186 whereas eukaryotes, prokaryotes, non-human viruses and human viruses with no variance or a 187 maximal summed epitope hit count below three were excluded. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint component analyses (PCA) were performed using stats (4.2.0) and factoextra (1.0.7) with 195 scaled, centered variables, and loadings are shown as variable coordinates. Spearman's rank 196 correlation was used for associations of numeric variables. Pairwise protein alignment for amino acid (AA) long peptides with SARS-CoV-2 spike (Uniprot Entry P0DTC2) and 198 nucleoprotein (P0DTC9) was generated using Biostrings (2.60.2), with BLOSUM62 199 substitution matrix and gap opening and extension penalty of -11 and -1, respectively. Data is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint

We performed a comprehensive immunological characterization of 175 individuals with 207 confirmed COVID-19 up to one year after infection ( Fig. 1A and Table 1, Table S1 ), including 208 autoantibody screening by IIF, serum proteomics and serological profiling. 41 individuals with 209 negative history and serology for SARS-CoV-2 infection were included as controls (Fig. 1A  210 and Table 1 ). Furthermore, eleven unexposed individuals were sampled before and after 211 vaccination with BNT162b2 (Table S2) . 212

Using a highly sensitive IIF screening assay, we detected titers of 1:320 and above in 17 of 41 213 (41.4%) healthy individuals thus testing positive for ANA (Fig. 1B) . This prevalence of ANA 214 positivity was similar to that in COVID-19 patients during acute disease (48.0%, odds ratio 215 (OR) = 1.30, p = 0.49) as well as six months (47.4%, OR = 1.27, p = 0.59) and one year after 216 recovery (42.3%, OR = 1.04, p = 1) ( Fig. 1C-E) . Most of the observed ANA titers were just 217 above the positivity threshold of 1:320. Interestingly, we observed a trend of higher ANA 218 prevalence in individuals with severe COVID-19 compared to mild disease during acute 219 infection (OR 1.85, p = 0.061), which was significantly higher at six months after recovery 220 (OR = 3.81, p = 0.0015) ( Fig. 1C and D) . 221

Similarly, we used an IIF assay to detect ANCA. ANCA prevalence was similar in mild 222 COVID-19 patients during acute disease (3.6%) compared to healthy individuals (2.4%) (Fig.  223 1F and G). Conversely, we observed a significantly higher ANCA prevalence in severe acute 224 , both compared to healthy subjects (p = 0.0082) and mild COVID-225 19 cases (p = 0.0096) ( Fig. 1F and G) , which returned to ranges seen in healthy individuals 226 after six months (5.1%, p = 0.61) and one year (14.3%, p = 0.15) ( Fig. 1H and I) . 227

In several patients, nuclear ANA, cytoplasmic ANA, or ANCA were detected concurrently, 228 particularly during acute COVID-19 ( Fig. 1J-M) . Moreover, ANCA showed a tendency to be 229 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint more frequent in ANA-positive (14.3%) compared to ANA-negative (5.5%) individuals during 230 acute COVID-19 (p = 0.06) (Fig. 1K) . 231 232 Characteristics of ANA and ANCA patterns in acute COVID-19 233

To gain a qualitative appreciation, we classified ANA patterns according to the international 234 consensus on ANA patterns anti-cell (AC) nomenclature (24). ANA patterns were very similar 235 in healthy controls and COVID-19 patients at all three sampling timepoints, and in some 236 participants different patterns were detected concurrently ( Fig. 2A-D, Fig. S1A-D) . The most 237 common nuclear patterns were fine-granular nuclear (AC-4 or AC-4 like) and nucleolar (AC-238 8, AC-9, and AC-10), whereas the most common cytoplasmic patterns were speckled (AC-19 239 and AC-20) (Fig. 2E-G) . 240 ANCA patterns observed during acute COVID-19 and follow-up were mostly cytoplasmic 241 ( Fig. 2H) . However, cytoplasmic patterns were atypical and, accordingly, none of the ANCA-242 positive patients showed positivity for either anti-myeloperoxidase (MPO) or anti-proteinase 3 243 (PR3) antibodies (Fig. 2I) , suggesting other antigen specificities than commonly found in 244 ANCA-associated vasculitis (31, 32). 245 246

To appreciate changes in ANA and ANCA on an individual level, we performed paired analysis 248 of all patients that attended at least one follow-up (n = 116 at six months and n = 13 at one 249 year). For ANA, we observed similar proportions of patients with isolated ANA positivity 250 during acute disease (14.7%) and during follow-up (12.4%) (Fig. 3A) . However, a trend toward 251 a higher proportion of new ANA development at follow-up visit was evident in patients with 252

severe COVID-19 (20.5%) compared to patients with mild COVID-19 (8.2%) (OR = 2.84, p = 253 0.054) (Fig. 3B) . To also account for subtle changes of IIF patterns, we conducted a blinded, 254 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint paired analysis of IIF images to identify patterns that were transiently present either during 255 acute disease or follow-up. Strikingly, we found transient patterns in 11 of 62 (17.7%) ANA-256 positive COVID-19 patients during acute disease, with speckled cytoplasmic , 257 nucleolar 9, 10) and mitotic being the most frequent patterns ( Fig. 3C and D) . In stark 258 contrast, only three of 59 (5.1%) ANA-positive individuals presented with a pattern during 259 follow-up that was not present during acute disease, thus demonstrating that transient ANA 260 patterns were significantly more prevalent during acute COVID-19 (p = 0.045) (Fig. 3C) . 261

For ANCA, we observed that of ten patients that tested positive during acute COVID-19, eight 262 were negative during follow-up, whereas only two remained positive (Fig. 3E) . Furthermore, 263 only one patient newly exhibited positive ANCA at follow-up ( Fig. 3E and F) . Collectively, 264 we found that a subgroup of individuals shows ANA and atypical ANCA production during 265 the acute phase of COVID-19, which usually subsides during follow-up. 266 267

To elucidate the influence of autoantibody production during acute infection, we investigated 269 the correlation of autoantibodies with specific humoral immune responses to SARS-CoV-2. 270

We longitudinally assessed SARS-CoV-2 spike 1 (S1)-specific immunoglobulin A (IgA) and 271

IgG titers and found that presence of ANA was associated with higher concentrations of S1-272 specific antibodies in COVID-19 patients during acute disease, which extended to six months 273 after recovery (Fig. 4A) . Conversely, one year after recovery, we did not observe any 274 differences (Fig. S2) . The presence of ANA correlated significantly with S1-specific IgG levels 275 even after accounting for age, disease severity, and sampling timepoint in a multiple linear 276 regression model, which was not the case of S1-specific IgA (Fig. 4B, Table S5 ). Similarly, 277

we found higher S1-specific IgA and a trend toward higher IgG titers in patients that tested 278 positive for ANCA during acute disease (Fig. 4C) . 279 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 To elucidate whether autoantibodies were associated with an increased humoral immune 280 response only after natural SARS-CoV-2 infection or also after other antigen-specific immune 281 responses, we measured ANA and S1-specific antibodies in 11 individuals before and after 282 COVID-19 vaccination with BNT162b2 ( Fig. 4D-F, Table S2 ). Although a tendency of an 283 increased ANA prevalence following the first vaccine shot was apparent, no significant 284 difference was observed between sampling timepoints (Fig. 4D) . We observed higher S1-285 specific IgA in ANA-positive individuals when combining data from two and four weeks after 286 the first vaccine shot, whereas no difference was observed for IgG ( Fig. 4E and F) . In summary, 287 these findings suggest the presence of autoantibodies is associated with increased S1-specific 288 humoral responses following acute COVID-19 up to six months after recovery and following 289 SARS-CoV-2 vaccination. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint A multivariate analysis using the summed epitope hits per viral species revealed distinct 304 differences in COVID-19 patients compared to healthy controls, which were particularly 305 pronounced more than one week after symptom onset (Fig. 5A) . Between-group comparisons 306 of COVID-19 patients and healthy controls revealed a significant difference (p < 0.005) of 307 summed epitope hits for eight viral species (Fig. 5B ). Of these, four enterovirus species were 308 more abundant in healthy controls. Conversely, antibodies targeting cytomegalovirus (CMV) 309 and Pegivirus A, and those directed to SARS-CoV and MERS-CoV were significantly more 310 abundant in COVID-19 patients, whereas antibodies targeting the four common coronaviruses 311

HCoV-HKU1, HCoV-NL63, HCoV-229E, and BCoV1, showed a parallel, but insignificant 312 trend (p > 0.005) (Fig. 5B) . Antibodies directed to all coronavirus species correlated positively 313 with time from symptom onset (Fig. 5C) , thus indicating production of cross-reactive 314 antibodies during acute To further study antibodies targeting CoVs in acute COVID-19, we evaluated serological 316 profiles on a singular epitope level. We found a significantly higher (p < 0.05) proportion of 317 COVID-19 patients tested positive for a total of 18 CoV epitopes compared to healthy controls, 318 of which 16 were in the spike and two in the nucleoprotein (Fig. 5D, Fig. S3A) . Since healthy 319 individuals tested negative for these but positive for only one epitope ( Fig. 5D and E), we 320 hypothesized these 18 CoV epitopes enriched in COVID-19 patients were targeted by 321 antibodies newly produced during acute COVID-19 and cross-reactive with shared epitopes of 322 other CoVs. Pairwise protein alignment of these epitopes with corresponding SARS-CoV-2 323 proteins allowed identification of regions of SARS-CoV-2 spike and nucleoprotein targeted by 324 cross-reactive antibodies, comprising two segments (AA positions 777-886 and 1105-1195) 325 of spike S2 domain and one segment of nucleoprotein (AA 140-252), which have been 326 previously identified in . Patients with severe COVID-19 tested 327 positive for significantly more cross-reactive antibodies than mild disease patients (Fig. 5E) . 328 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint However, no significant difference was observed in ANA-positive compared to ANA-negative 329 patients (Fig. 5F) , although the proportion of ANA-positive patients that tested positive was 330 slightly higher for most cross-reactive epitopes (Fig. 5G) . 331

To explore potential correlations of ANA with humoral responses against other viruses, we 332 compared seroreactivity against all tested viral epitopes and ANA positivity. Several epitopes 333 were detected more frequently (p < 0.005) in ANA-positive, but not in ANA-negative, 334 individuals (Fig. 5H) . Three of the identified peptides were located on Epstein-Barr virus 335 (EBV) nuclear antigen 2 (EBNA-2), to which ANA-positive participants showed more epitope 336 hits, independent of age ( Fig. S3B) . When combining data of all available epitopes, we found 337 significantly more hits in ANA-positive compared to ANA-negative participants, which was 338 most pronounced at younger age (Fig. 5I) . Thus, human virome-wide serological profiling in 339 acute COVID-19 revealed antibodies cross-reactive to other coronaviruses, whereas ANA-340 positive participants producing antibodies to more viral epitopes on a virome wide level. 341 342

Several studies have associated autoantibodies with severe 15, [17] [18] [19] . Thus, 344 we sought to further characterize ANA-positive and ANA-negative COVID-19 patients during 345 acute disease by proteomics comprising 86 inflammatory markers, cytokine measurements, 346 flow cytometry, clinical history, and routine diagnostic analyses. The proportion of participants 347 with a known autoimmune disease was low in our cohort and indifferent in individuals with or 348 without ANA or ANCA ( Table 2) . We found a higher prevalence of comorbidities in 349 autoantibody-positive patients, including hypertension and heart disease, but no significant sex 350 difference ( Table 2) . 351

A multivariate analysis with 130 variables, including demographic parameters, routine 352 diagnostic measurements, and inflammation markers obtained by proteomics (Table S6) , 353 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint allowed for a nearly complete separation of severe COVID-19 patients from healthy 354 individuals, with mild COVID-19 patients exhibiting intermediate characteristics (Fig. 6A) . 355

Several markers contributing to severe COVID-19 were significantly higher (p < 0.05) in 356 ANA-positive than ANA-negative COVID-19 patients, revealing an inflammatory signature 357 associated with severe disease in ANA-positive individuals (Fig. 6B) . Importantly, ANA-358 positive COVID-19 patients were older and experienced longer hospitalization (Fig. 6C) , and 359 many inflammation markers, including C-reactive protein (CRP) and interleukin (IL)-6, were 360 elevated compared to ANA-negative patients (Fig. 6D) . Furthermore, ANA-positivity was 361 associated with T cell activation as suggested by higher soluble IL-2 receptor alpha (sIL-2Rα) 362 serum concentrations and increased proportions of activated CD38 + HLA-DR + CD4 + and CD8 + 363 T cells (Fig. 6E) . Similar trends toward an inflammatory signature were also observed in 364 ANCA-positive individuals during acute COVID-19, although these results were limited due 365 to lower prevalence of ANCA ( Fig. S4A and B) . Table S7 ), with several inflammation markers, including IL-6, tumor necrosis factor 371 alpha (TNF-α), and sIL-2Rα, being significantly higher in ANA-positive participants (Fig. 6F  372 and G, Table S7 ). Interestingly, we also observed differences in Ig subclasses, with 373 significantly higher IgG1 and significantly lower IgM in ANA-positive individuals (Fig. 6H) . 374 Furthermore, marked changes in B cell subsets were apparent, with higher frequencies of IgD + 375 CD27naïve B cells and lower frequencies of IgD + CD27 + non-switched and IgD -CD27 + 376 switched memory B cells in ANA-positive individuals (Fig. 6I) . Altogether, in autoantibody-377 positive COVID-19 patients, we found an inflammatory signature during acute disease 378 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint resembling alterations found in severe disease and changes in inflammation markers, Ig 379 subclasses, and B cells at six months after recovery. 380 381 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint

Although autoantibodies targeting nuclear, cytoplasmic, and soluble autoantigens following 383 viral infections have been well described (35, 36) , their significance has remained ill-defined. 384

In this study, we used highly sensitive assays to detect ANA and ANCA, representing systemic 385 autoantibodies, in patients up to one year after infection with SARS-CoV-2. Firstly, we found 386 transient ANA and ANCA in a subgroup of participants during acute COVID-19. Autoantibody 387 production could result from activation of autoreactive B and T cells recognizing viral epitopes 388 by means of molecular mimicry (37, 38). Alternatively, antigen-independent 'bystander' 389 activation of autoreactive B and T cells by cytokines and other inflammatory mediators could 390 drive autoantibody production (28, 39). Particularly in severe COVID-19, which is associated 391 with early neutrophilia and pronounced neutrophil extracellular trap (NET) formation (40, 41), 392

NETs expose shielded intracellular self-antigens (32, 42, 43), thus causing production of 393 ANCA and ANA. Interestingly, a high prevalence of IgA ANCA has been reported in acute 394 COVID-19 patients showing chilblain-like lesions (21). In our study, all ANCA-positive 395 subjects tested negative for anti-MPO and anti-PR3 antibodies, thus it remains elusive whether 396 these ANCA have pathogenic potential. 397 Secondly, we found distinct features in autoantibody-positive COVID-19 patients during acute 398 disease and recovery. Autoantibodies were associated with prolonged hospitalization and 399 inflammation markers during acute disease, supporting recent findings (11, 15, 17-19, 44, 45) . 400

Whereas autoantibodies targeting type I interferons have been linked to severe COVID-19 (10-401 12, 16), severe COVID-19 could decrease self-tolerance by tissue damage and inflammation, 402 altogether leading to generation of autoantibodies. However, confounding factors should be 403 considered, such as age and comorbidities, affecting prevalence of autoantibodies and risk of 404 severe COVID-19. Following these considerations, we found changes in ANA-positive 405 individuals even six months after acute COVID-19, indicating ongoing low-grade 406 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint inflammation. Furthermore, we observed alterations of the B cell compartment, including 407 increased naïve and decreased memory B cells, previously associated with pre-symptomatic 408 and early-stage autoimmune diseases (46-48). Differences in total Ig concentrations have been 409 found in autoimmune diseases (49) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint potentially explaining why individuals with autoantibodies exhibit higher humoral responses 432 during acute COVID-19. Whether autoantibody-positive subjects also show increased SARS-433

CoV-2-specific long-lived T cells responses (55) remains to be investigated. 434

Limitations of this study include the use of highly sensitive IIF assays that yielded a high 435 prevalence of positive results in healthy subjects and COVID-19 patients. Most of the measured 436 ANA titers were at or just above the threshold level, which usually would be considered of 437 irrelevant clinical significance. Moreover, we did not assess the specificity of autoantibodies, 438 but recent studies have shown reactivity to a wide spectrum of autoantigens (11, 16) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint Hypertension (n) 5 (12.2%) 12 (11.0%) ns 38 (57.8%)*** 6 (7.8%) ns 21 (53.8%)** Diabetes (n) 2 (4.9%) 6 (5.5%) ns 19 (28.8%)* 4 (5.2%) ns 12 (30.7%)** Heart disease (n) 1 (2.4%) 6 (5.5%) ns 24 (36.6%)*** 2 (2.6%) ns 15 (38.5%)*** Lung disease (n) 5 (12.2%) 10 (9.2%) ns 12 (18.8%)* 5 (6.5%) ns 11 (28.2%) ns Malignancy (n) 1 (2.4%) 3 (2.8%) ns 8 (12.1%)** 3 (3.9%) ns 5 (12.8%) ns Kidney disease (n) 0 (0%) 8 (7.3%) ns 17 (25.8%)*** 3 (3.9%) ns 10 (25.6%)** Autoimmune disease (n) 3 (7.3%) 6 (5.5%) ns 7 (10.6%) ns 6 (7.8%) ns 6 (15.4%) ns is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint Chi-squared test of independence. (E) S1-specific IgA and IgG before and after COVID19 666 vaccination (n = 11). Red vertical lines indicate the timepoints of first and second vaccination 667 with BNT162b2. (F) S1-specific IgA and IgG in ANA-positive and ANA-negative participants 668 following COVID-19 vaccination with BNT162b2, combining data from 10-13d after the first 669 (n = 11) and 1-3d after the second (n = 10) vaccination. 670 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 including all available epitopes, comparing ANA-negative and ANA-positive participants (top; 696 n = 115), and as a function of age (bottom). 697

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 group with higher mean, and parameters with significant differences (p < 0.05) comparing 739 ANCA-positive and ANCA-negative COVID-19 patients are shown as large dots and 740 annotated. 741 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint Figure 3 A B is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268901 doi: medRxiv preprint

Coronavirus Disease 2019 in China

Comparing 466 SARS-CoV-2 with SARS-CoV and influenza pandemics

COVID-19): A 470 Review

COVID-19 and autoimmune diseases

Antiphospholipid Antibodies in Patients with Covid-19

Barré Syndrome Associated with SARS-CoV-2

The 478 Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19

Prothrombotic 481 autoantibodies in serum from patients hospitalized with COVID-19

Incident systemic 484 rheumatic disease following COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Diverse functional 489 autoantibodies in patients with COVID-19

Autoantibodies 491 neutralizing type I IFNs are present in

Molecular mimicry, bystander 493 activation, or viral persistence: infections and autoimmune disease

Autoantibodies related to systemic autoimmune rheumatic diseases in 497 severely ill patients with COVID-19

CoV-2 infection as a trigger of autoimmune response

IgG autoantibodies in hospitalized patients with COVID-19

COVID-503 19 and Immunological Dysregulation: Can Autoantibodies be Useful?

Autoantibodies in moderate and critical cases of COVID